Related Experiment Video
Updated: Aug 10, 2026
09:00
An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles
Published on: March 18, 2015
Furanonaphthoquinone analogs possessing preferential antitumor activity compared to normal cells
1Department of Anatomy, Kanazawa Medical University, Uchinada, Ishikawa, Japan. keih@kanazawa-med.ac.jp
Cancer Detection and Prevention
|November 26, 1999
Summary
Two furanonaphthoquinone analogs, FNQ3 and FNQ13, show preferential antitumor activity against various human cancer cells. These compounds exhibit selective cytotoxicity, offering potential for targeted cancer therapies.
Area of Science:
- Medicinal Chemistry
- Cancer Biology
- Pharmacology
Background:
- Furanonaphthoquinones (FNQs) are a class of compounds with potential anticancer properties.
- Developing selective anticancer agents that spare normal cells is a critical challenge in oncology.
Purpose of the Study:
- To evaluate the in vitro and in vivo antitumor activity of synthetic and natural furanonaphthoquinone analogs.
- To determine the structure-activity relationship for selective cytotoxicity against cancer cells.
Main Methods:
- In vitro cytotoxicity assays (IC50) were performed on a panel of human cancer and normal cell lines.
- Structure-activity relationship analysis was conducted based on IC50 ratios.
- In vivo antitumor activity was assessed using nude mouse xenograft models.
Main Results:
- Two analogs, FNQ3 and FNQ13, demonstrated broad-spectrum preferential antitumor activity with high IC50 ratios (10.4–14.1) against various carcinoma and osteosarcoma cells.
- Specific structural features, including an alkyl group at position 2 and a hydroxyl group at position 5 or 8, enhanced selectivity.
- FNQ3 showed significant in vivo antitumor activity in xenograft models.
Conclusions:
- FNQ3 and FNQ13 exhibit promising selective cytotoxicity against human tumor cells.
- These furanonaphthoquinone analogs represent potential leads for developing novel anticancer drugs with improved safety profiles.
- Structural modifications can be used to optimize the antitumor efficacy and selectivity of FNQs.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:28Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...